Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B96 phase 3 trial of pembrolizumab versus placebo with weekly paclitaxel with or without bevacizumab in platinum-resistant recurrent ovarian cancer
MOH_2021-11-09_010331Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Pembrolizumab arm with Placebo arm (2 arms). Started Nov 2021; status: active, not recruiting.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2021-11-09_010331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-09_010331.